Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system that mainly affects young adults. Therapeutic options for MS have moved forward significantly in the last twenty years.
In denial of interest, there is currently a biological treatment based on monoclonal antibodies directed against CD20, the surface antigen of B lymphocytes. Their effectiveness in the treatment of MS has been proven in clinical studies.
Ofatumumab is a fully human anti-CD20 monoclonal antibody approved for the treatment of adult patients with active relapsing-remitting MS (RR-RS) defined clinically or by imaging methods. This is the first B cell therapy intended for subcutaneous application at home once a month.
Research confirms that the early use of a highly effective substance (high efficacy therapy, HET) slows the progression of disability and improves the long-term prognosis, especially in younger patients with active RR-RS disease. In the Czech Republic, after ocrelizumab, ofatumumab is only the second drug from the HET group to receive reimbursement from public health insurance funds as part of the first-line treatment of RR-RS.